Sandostatin

Phase 2Small molecule

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Sandostatin is one of 86 small molecule programs targeting Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Prostate CancerActive, not recruiting

AcromegalyActive, not recruiting

Breast CancerPreclinical

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

AcromegalyPreclinical

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tykerb

GSK

Preclinical

80 2

Adriamycin

GGynecologic Oncology Group

Preclinical

87 3

Avastin

BBio-Thera Solutions

Preclinical

153 4

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 5

Prolia

Amgen

Preclinical

14 6

Gemzar

GGynecologic Oncology Group

Preclinical

22 7

MS Contin

Merck & Co.

Preclinical

2 8

Adenocard

Astellas

Preclinical

1 9

Voltaren

Novartis

Preclinical

1 10

Zolymbus

AbbVie

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2051

Recruiting

Acromegaly

NCT03158090

Clinical

Trials by Indication[1]

Prostate Cancer1 trial

Sandostatin for Patients With Androgen Independent Prostate Cancer

Terminated·UUniversity of California, San Francisco·Phase 2·NCT00510224·13 enrolled

Acromegaly1 trial

The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research

Recruiting·GGinkgo Leaf Center for Rare Disorders··NCT03158090·1,965 enrolled

Statin1 trial

Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation

Terminated·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·Phase 4·NCT04140409·10 enrolled

Breast Cancer1 trial

Stress, Diurnal Cortisol, and Breast Cancer Survival

Completed·SStanford University··NCT00226967·115 enrolled

Adult Subject1 trial

A Single-dose Study of Octreotide Injection in Healthy Adult Subjects

Completed· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT05761431·56 enrolled

1 more indication

Surgery1 trial

Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues

Unknown status·—·Phase 4·NCT02427295·1 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Sandostatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sandostatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sandostatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSPC ZhongQi Pharmaceutical Technology Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Sandostatin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2051

Trials by Indication[1]

Prostate Cancer1 trial

Acromegaly1 trial

Statin1 trial

Breast Cancer1 trial

Adult Subject1 trial

Surgery1 trial

References

Drug Info

Quick Facts

Related News